Mantle Cell Lymphoma Clinical Trials in Portland, Oregon

8 studies are recruiting for mantle cell lymphoma in Portland, Oregon right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

  1. A Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell Malignancies

    The purpose of this study is to assess the safety and efficacy of surovatamig (formerly AZD0486) administered as monotherapy or in combination with other anticancer agents in participants with hematological malignancies

    Stage
    Phase 1
    Ages
    18 and older
    Site
    Research Site, Portland, Oregon
    Locations
    65 in total
    Run by
    AstraZeneca
  2. Testing Continuous Versus Intermittent Treatment With the Study Drug Zanubrutinib for Older Patients With Previously Untreated Mantle Cell Lymphoma

    This phase III trial tests whether continuous or intermittent zanubrutinib after achieving a complete remission (CR) with rituximab works in older adult patients with mantle cell lymphoma (MCL) who have not received treatment in the past (previously untreated). Rituximab is a monoclonal antibody th…

    Stage
    Phase 3
    Ages
    60 and older
    Site
    Providence Portland Medical Center, Portland, Oregon
    Locations
    238 in total
    Run by
    Alliance for Clinical Trials in Oncology
  3. Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)

    This is a Phase 1/2, first-in-human, open-label, dose-escalating trial designed to assess the safety and efficacy of VNX-101 in patients with relapsed or refractory CD19-positive hematologic malignancies.

    Stage
    Phase 1
    Ages
    13 to 90
    Site
    Oregon Health & Science University, Portland, Oregon
    Locations
    11 in total
    Run by
    Vironexis Biotherapeutics Inc.
  4. A Long-term Extension Study of PCI-32765 (Ibrutinib)

    The purpose of this study is to collect long-term safety and efficacy data for participants treated with ibrutinib and to provide ongoing access to ibrutinib for participants who are currently enrolled in ibrutinib studies that have been completed according to the parent protocol, are actively rece…

    Stage
    Phase 3
    Ages
    18 and older
    Site
    Kaiser Permanente, Portland, Oregon
    Locations
    175 in total
    Run by
    Janssen Research & Development, LLC
  5. Study of SGR-1505 in Mature B-Cell Neoplasms

    The purpose of this study is to evaluate safety and tolerability and to determine the maximum tolerated dose (MTD) or maximum administered dose (MAD) and/or recommended dose (RD) of SGR-1505.

    Stage
    Phase 1
    Ages
    18 and older
    Site
    Oregon Health and Science University - Knight Cancer Institute, Portland, Oregon
    Locations
    36 in total
    Run by
    Schrödinger, Inc.
  6. Glofitamab Plus Ibrutinib With Obinutuzumab for the Treatment of Patients With Mantle Cell Lymphoma, IGNITE MCL Trial

    This phase IB/II trial tests the safety, side effects and effectiveness of glofitamab plus ibrutinib with obinutuzumab for the treatment of patients with mantle cell lymphoma (MCL). Glofitamab is in a class of medications called bispecific monoclonal antibodies. It works by killing cancer cells. A …

    Stage
    Phase 1
    Ages
    18 and older
    Site
    OHSU Knight Cancer Institute, Portland, Oregon
    Run by
    OHSU Knight Cancer Institute
  7. SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry

    International registry for cancer patients evaluating the feasibility and clinical utility of an Artificial Intelligence-based precision oncology clinical trial matching tool, powered by a virtual tumor boards (VTB) program, and its clinical impact on pts with advanced cancer to facilitate clinical…

    Stage
    Not phased
    Ages
    Any age
    Site
    Massive Bio SYNERGY-AI site, Portland, Oregon
    Locations
    68 in total
    Run by
    Massive Bio, Inc.
  8. Vaccine Responses in Patient With Multiple Myeloma and Non-Hodgkin Lymphoma After CAR-T Treatment

    This study evaluates immune responses after CAR-T therapy to find out if CAR-T therapy reduces the effectiveness of the vaccines (vaccine immunity) against diseases such as measles, mumps and rubella, among others in patients with multiple myeloma and non-Hodgkin lymphoma.

    Stage
    Not phased
    Ages
    18 and older
    Site
    OHSU Knight Cancer Institute, Portland, Oregon
    Run by
    OHSU Knight Cancer Institute

How to read this page. Every study here comes from ClinicalTrials.gov, the public registry that research teams are required to file with. We have summarised each one in plain language and shown where it is running. We have not changed what any study says it is doing.

What TrialBoost is. We help people find research that might suit them, and, if they ask us to, we pass their details to the research team running it. We are not a doctor, a research site, or a study sponsor, and we do not decide who takes part in anything. Joining costs nothing and you can change your mind at any point.

Paid placement. Some studies pay us when someone asks to be connected to them. Those are labelled Sponsored wherever they appear, and they only appear when they match what you were actually looking for.